AU2011276552B2 - Oral formulation of kinase inhibitors - Google Patents

Oral formulation of kinase inhibitors Download PDF

Info

Publication number
AU2011276552B2
AU2011276552B2 AU2011276552A AU2011276552A AU2011276552B2 AU 2011276552 B2 AU2011276552 B2 AU 2011276552B2 AU 2011276552 A AU2011276552 A AU 2011276552A AU 2011276552 A AU2011276552 A AU 2011276552A AU 2011276552 B2 AU2011276552 B2 AU 2011276552B2
Authority
AU
Australia
Prior art keywords
formulation
peg
fak
oil
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011276552A
Other languages
English (en)
Other versions
AU2011276552A1 (en
Inventor
Andrew Xian Chen
Yali J. Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of AU2011276552A1 publication Critical patent/AU2011276552A1/en
Assigned to VERASTEM, INC. reassignment VERASTEM, INC. Request for Assignment Assignors: PONIARD PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2011276552B2 publication Critical patent/AU2011276552B2/en
Priority to AU2015261692A priority Critical patent/AU2015261692A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011276552A 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors Ceased AU2011276552B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015261692A AU2015261692A1 (en) 2010-06-29 2015-11-27 Oral formulation of kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35969410P 2010-06-29 2010-06-29
US61/359,694 2010-06-29
PCT/US2011/042162 WO2012006081A1 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015261692A Division AU2015261692A1 (en) 2010-06-29 2015-11-27 Oral formulation of kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2011276552A1 AU2011276552A1 (en) 2013-01-10
AU2011276552B2 true AU2011276552B2 (en) 2015-09-03

Family

ID=45441513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011276552A Ceased AU2011276552B2 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Country Status (10)

Country Link
US (1) US9375402B2 (enExample)
EP (1) EP2588081A4 (enExample)
JP (1) JP5936609B2 (enExample)
CN (1) CN103313697B (enExample)
AU (1) AU2011276552B2 (enExample)
CA (1) CA2803004A1 (enExample)
MX (1) MX340819B (enExample)
NZ (1) NZ604583A (enExample)
WO (1) WO2012006081A1 (enExample)
ZA (1) ZA201300009B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
CN104427977B (zh) 2012-05-10 2018-02-02 佩因拉佛姆有限公司 局部麻醉剂的储库制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080193518A1 (en) 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
BRPI0715423A2 (pt) 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
EP2464642A4 (en) 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase

Also Published As

Publication number Publication date
MX2012014982A (es) 2013-07-03
US9375402B2 (en) 2016-06-28
AU2011276552A1 (en) 2013-01-10
ZA201300009B (en) 2013-09-25
US20140206692A1 (en) 2014-07-24
CA2803004A1 (en) 2012-01-12
JP5936609B2 (ja) 2016-06-22
JP2013529686A (ja) 2013-07-22
NZ604583A (en) 2015-04-24
MX340819B (es) 2016-07-26
WO2012006081A1 (en) 2012-01-12
CN103313697A (zh) 2013-09-18
CN103313697B (zh) 2016-06-01
EP2588081A4 (en) 2014-12-10
EP2588081A1 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
EP3431075B1 (en) Edaravone dosage form
AU724842B2 (en) Taxane composition and method
GB2572126A (en) Pharmaceutical
US20070104780A1 (en) Formulation comprising a drug of low water solubility and method of use thereof
MXPA03000720A (es) Sistemas auto-emulsificantes de suministro de medicamentos para medicamentos lipofilicos extremadamente insolubles en agua.
US12558321B2 (en) Pharmaceutical formulation
JP2007509978A (ja) トコフェロール修飾治療薬化合物
KR20100023862A (ko) 트윈 80을 함유하지 않은 도세탁셀의 용해 제제
US6316497B1 (en) Self-emulsifying systems containing anticancer medicament
US9375402B2 (en) Oral formulations of kinase inhibitors
EA016619B1 (ru) Новые композиции на основе таксоидов
RU2639482C2 (ru) Фармацевтические композиции
AU2004262496B2 (en) Semi-solid formulations for the oral administration of taxoids
CN115850248A (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
CN113979954A (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
US20110130446A1 (en) Injectable taxane pharmaceutical composition
JP2015522063A (ja) ネパデュタントを含有する小児用経口液体組成物
CA2612288A1 (en) Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
KR101612259B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
AU2007262493A1 (en) Pharmaceutical composition for oral administration
WO2011050457A1 (en) Stabilized formulation for oral administration of therapeutic agents and related methods
JP2013503876A (ja) インジブリンに関する薬学的組成物
Nagarsenker et al. Preformulation Studies for Microemulsion Formulation
AU2015261692A1 (en) Oral formulation of kinase inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VERASTEM, INC.

Free format text: FORMER APPLICANT(S): PONIARD PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired